key: cord-0973368-vjcalf3j authors: Topless, R.; Phipps-Green, A.; Leask, M.; Dalbeth, N.; Stamp, L.; Robinson, P.; Merriman, T. title: Gout, rheumatoid arthritis and the risk of death from COVID-19: an analysis of the UK Biobank date: 2020-11-09 journal: nan DOI: 10.1101/2020.11.06.20227405 sha: 003e618cdc0a9a8e90840e44aac2013d4d760db7 doc_id: 973368 cord_uid: vjcalf3j Objectives To assess whether gout and / or rheumatoid arthritis (RA) are risk factors for coronavirus disease 19 (COVID-19) diagnosis. To assess whether gout and / or RA are risk factors for death from COVID-19. Methods We used data from the UK Biobank. Multivariate-adjusted logistic regression was employed in the following analyses. Analysis A: to test for association between gout or RA and COVID-19 diagnosis in a population-based cohort (n=473,139). Analysis B: to test for association between gout or RA and death from COVID-19 in a case-control cohort of people who died or survived with COVID-19 (n=2,073). Analysis C: to test for association with gout or RA and death from COVID-19 in a population-based cohort (n=473,139) Results Neither RA nor gout associated with COVID-19 diagnosis in analysis A, nor did RA or gout associate with risk of death in the COVID-19-diagnosed group in analysis B. However RA associated with risk of death from COVID-19 using the population-based cohort in analysis C independent of comorbidities and other measured risk factors (OR=1.8 [95% CI 1.2 ; 2.7]). Gout was not associated with death from COVID-19 in the same population-based analysis (OR=1.2 [95% CI 0.9 ; 1.7]). Conclusions RA and gout are not risk factors for COVID-19-diagnosis. However RA, but not gout, is a risk factor for death from COVID-19 in a population-based analysis using the UK Biobank. These findings require replication in larger data sets that also allow inclusion of a wider range of factors. Data on coronavirus disease 2019 (COVID-19) outcomes for people with the two most common inflammatory arthropathies, gout and rheumatoid arthritis (RA), are scarce. An international registry study of 600 people with rheumatic diseases did not report any data on association of gout with hospitalisation, owing to the small number of people with gout included (1). In the same study, people with RA did not have a different risk of hospitalisation compared to other rheumatic diseases (1). In the OpenSAFELY study (2) that compared risk factors for 10,926 people who died from COVID-19 to the general population in the UK, RA was pooled with systemic lupus erythematosus and psoriasis, this combined group had a hazard ratio of 1.2 [95% CI: 1.1;1.3] for death. Gout was not examined in the OpenSAFELY study. In a US study comparing people with COVID-19 with systemic autoimmune rheumatic diseases, of whom 45% had RA, to people without these diseases there was increased risk of hospitalisation and admission to intensive care but not death (3) . A Spanish study reported no evidence for association of chronic inflammatory arthritis (48% with RA) with poor outcome in COVID-19 (4) . Gout is caused by an exuberant auto-inflammatory interleukin-1β-driven innate immune system response to monosodium urate crystals present in joints (5) . Theoretically this has the potential to lead to an increased immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Poorer COVID-19 outcomes have been associated with high serum levels of IL-6, IL-8 and TNF-α (6) , raising the possibility that people with gout might be at risk of a poor outcome due to the fact that they also have higher circulating levels of these factors (7) . Gout is also strongly associated with cardiometabolic co-morbidities such as type 2 diabetes, kidney disease and heart disease (8) , all established risk factors for COVID-19-related mortality (2) . Gout medications may also influence outcomes following the development of COVID-19: two randomised control trials of colchicine, which is widely used as prophylaxis and treatment for the gout flare (9) , reported better clinical outcomes including a shorter time in hospital and shorter duration requiring supplemental oxygen in people hospitalised with COVID-19 in those randomised to colchicine (10, 11) . There is also non-randomised evidence of the efficacy of colchicine in COVID-19 in a small case-control study (12). . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227405 doi: medRxiv preprint Rheumatoid arthritis is a T-cell and B-cell mediated autoimmune disease that primarily affects the joints but also includes systemic manifestations. Like gout, RA is an independent risk factor for cardiovascular disease (13) . The profile of RA includes increased levels of proinflammatory cytokines TNF-α and IL-6 (14), a similar profile to COVID-19 (15) , with the potential to lead to an increased immune response to infection by SARS-CoV-2. The aim of this study was to determine if gout and RA are risk factors for COVID-19 diagnosis or death from COVID-19. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227405 doi: medRxiv preprint This research was conducted using the UK Biobank Resource (approval number 12611). SARS-CoV-2 test information, ICD-10 hospital codes, death records and general practice prescription information was obtained via the UK Biobank data portal on the 16 th of September 2020. This information covered hospital diagnoses between 1991 and 30 th June 2020, SARS-CoV-2 tests between 16 th March and 24 th August 2020, and death records up until 14 th August 2020. The criteria for COVID-19 diagnosis was defined as participants with 1. a positive SARS-CoV-2 test and / or 2. ICD-10 code for confirmed COVID-19 (U07.1) or probable COVID-19 (U07.2) in hospital records, or death records ( Figure 1 ). This definition resulted in identification of 2,118 individuals who were further divided into those that died (n=457) based on death records and those that were known to survive (n = 1,616). Forty-five participants who were diagnosed after the last recorded death were removed from this cohort used in Analysis B (below). Gout was ascertained by a previously validated gout definition using the following criteria: self-reported gout (visits 0-2); taking allopurinol or sulphinpyrazone therapy either by self-report or from linked general practice scripts (excluding those who also had hospital diagnosed lymphoma or leukemia ICD10 C81 -C96); or hospital-diagnosed gout (ICD-10 code M10) (16) . The gout case-control cohort (n = 473,139) consists of 13,105 cases (gout) and 460,034 controls (non-gout). RA affection was ascertained using the ICD-10 code M05 -M06. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227405 doi: medRxiv preprint Dataset C (Analysis C) to test for association with death from COVID-19 in a populationbased cohort. There were 457 people diagnosed with COVID-19 who died and 472,682 others that included 1,616 people diagnosed with COVID-19 not known to have died. Ethnicity, age and comorbidity data (pulmonary heart disease), I50 (heart failure), J44 (chronic obstructive pulmonary diseases), J45 (asthma), M19.9 (osteoarthritis) and N18 (chronic kidney disease). All association analyses were done using R v4.0.2 in RStudio 1.2.5019. Two models were used: adjustment with age, sex, ethnicity, Townsend deprivation index, BMI, smoking status (Model 1); and Model 1 plus adjustment by the 15 other co-morbidities evaluated (Model 2). A P < 0.05 threshold indicated nominal evidence for association. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227405 doi: medRxiv preprint Results from the association analyses of 16 diseases (including gout and RA) with COVID-19 diagnosis (Analysis A) using Model 1 (adjustment by current age, sex, Townsend deprivation index, ethnicity groups, body mass index and smoking status) are presented in Table 2 . Both gout and RA associated with an increased risk of COVID-19 diagnosis of 1. 5 Table 3 ). This decreased risk may reflect a number of factors that influence exposure to SARS-CoV-2 in this age group, including public health messaging around limiting exposure for older people. When testing for association with death from COVID-19 within the cohort with COVID-19 diagnosis (Analysis B), there was no evidence for association with any disease in either of Models 1 or 2 (Tables 2 and 3 In contrast, RA associated with increased risk of death from COVID-19 in both models -. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 9, 2020. We also assessed in Analysis C the 14 additional diseases for association with death from COVID-19 comparing to the entire population-based cohort. Dementia, immunodeficiencies, chronic obstructive pulmonary diseases, cerebrovascular diseases, heart failure, pulmonary heart disease, chronic kidney disease, hypertensive diseases, diabetes mellitus, and cancer all associated with additional risk of death in Model 2 (Table 3) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227405 doi: medRxiv preprint We identified RA, but not gout, as a risk factor for death from COVID-19 in a multivariate adjusted population-based analysis. A parallel can be drawn with the increased risk of death from COVID-19 we observed in immunodeficiencies, in that suppression of the immune system in RA using immunosuppressive disease-modifying anti-rheumatic drugs may affect the same pathway(s) contributing to death from COVID-19. Of relevance is the implication of a type 1 interferon-mediated immune response in people who die from COVID-19 (18) , including in people with mutations in regulatory genes (19) given mplication of the type 1 interferon response in therapy of RA with biologics (20) . There are limitations to our analyses. Firstly, these analyses pertain to the population from which the UK Biobank was derived, predominantly the white European middle-aged ethnic group of the United Kingdom, and are not necessarily generalisable to other ethnic groups or other white European ethnic groups. There is also no available information on recovery status so there is the possibility of additional unidentified deaths in the COVID-19 diagnosed group in Analysis B. In addition to this COVID-19 outcomes will have been influenced over the time period of this study (March-August 2020) as clinical treatments evolved. General practice prescriptions were only available up until August 2019 and could not reliably be used to determine current medication usage. Thus the effect of anti-rheumatic treatments, particularly biologic disease-modifying anti-rheumatic drugs, could not be assessed in this study. Limited testing outside of the hospital settings means that the full extent of SARS-CoV-2 infection is not known in this population thus it is not possible to accurately compare asymptomatic or mild COVID-19 to those with more severe disease. The UK Biobank dataset is also limited to those aged age 49 years to 86 years of age as of 2020, a demographic with a higher infection fatality ratio (21) . This undoubtedly will have contributed to the inflated infection fatality ratio in the UK Biobank cohort of 22%, well above general population estimates of 0.5 to 1.5% (e.g. (22)). Therefore our findings cannot be generalised to those under 50 years of age. Finally, there is the potential in Analysis B for index event (collider) bias resulting from conditioning the sample set on COVID-19 diagnosis which would serve to bias towards the null (23). However this limitation was addressed using the population-based approach in Analysis C. It is important that the findings presented here are replicated in larger administrative datasets (eg. US-based National COVID Cohort Collaborative (www.ncats.nih.gov/n3c) and the UK . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227405 doi: medRxiv preprint OpenSAFELY cohort (2)). These datasets would allow for more stratification and use of additional models to fully explore factors including medications that might influence the observed association with RA. For example, the OpenSAFELY study included 962 individuals who died with COVID-19 who also had RA or SLE or psoriasis (2) -the number of people with RA in this group is likely to be at least 10-fold greater than in UK Biobank data set used here. If our association were replicated, investigation of the reasons for the relationship between RA and death from COVID-19 would improve understanding and potentially improve clinical management of COVID-19. It will also be important to test for association with death from COVID-19 of RA alone, i.e. not with other autoimmunities with rheumatological sequelae, as was done in the OpenSAFELY cohort (2) . In summary, we found evidence for an effect of RA on the risk of a COVID-19 related death independent of comorbidities and known risk factors. We found an increased risk of death from RA, and this needs to be further explored in large datasets where a range of other factors can be investigated (e.g. RA therapies). . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227405 doi: medRxiv preprint This research has been conducted using the UK Biobank Resource under Application Number 12611. We thank all participants. The research was funded by the Health Research Council of New Zealand. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227405 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227405 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227405 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 9, 2020. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry Factors associated with COVID-19-related death using OpenSAFELY COVID-19 outcomes in patients living with rheumatic diseases Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study Advances in our understanding of gout as an auto-inflammatory disease An inflammatory cytokine signature predicts COVID-19 severity and survival What makes gouty inflammation so variable Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities Colchicine prophylaxis of gout flares when commencing allopurinol is very cost effective Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout COVID-19 revisiting inflammatory pathways of arthritis Performance of gout definitions for genetic epidemiological studies: analysis of UK Biobank Autoantibodies against type I IFNs in patients with life-threatening COVID-19 Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Dynamics of the type I interferon response during immunosuppressive therapy in rheumatoid arthritis Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy Serology-informed estimates of SARS-COV-2 infection fatality risk in